The most common gaps in regulatory submission dossiers fall into four main categories: incomplete or inconsistent Chemistry, Manufacturing and Controls (CMC) data, missing or insufficient clinical and non-clinical evidence, formatting and administrative errors, and product-specific gaps unique to biologics or ATMPs. These issues affect submissions across all regulatory frameworks, from EMA centralized procedures to national applications, and they are among the leading reasons agencies issue Lists of Outstanding Issues or refuse to validate dossiers. The sections below break down each gap type and explain how to address them before submission.
Why do regulatory dossiers get rejected or questioned?
Regulatory dossiers are rejected or questioned when they fail to provide sufficient evidence that a product is safe, effective, and consistently manufactured to an acceptable quality standard. Agencies such as the EMA or national competent authorities issue questions when data is missing, inconsistent, or does not align with current guidelines. In most cases, the underlying cause is not a single critical flaw but a combination of smaller gaps that collectively undermine the dossier’s credibility.
Common triggers for rejection or major questions include outdated references to superseded guidelines, misalignment between the summary documents and the actual study reports, and failure to justify deviations from standard requirements. Agencies expect applicants to anticipate their questions and address them proactively. When a dossier reads as though it was assembled in a hurry, with cross-references that lead nowhere or sections that contradict each other, reviewers lose confidence in the entire application. Working with an experienced regulatory affairs partner can help ensure your dossier is coherent, complete, and reviewer-ready from the outset.
What are the most frequent CMC gaps in submission dossiers?
The most frequent CMC gaps in regulatory submissions involve inadequate characterization of the drug substance or drug product, insufficient process validation data, and incomplete specification justification. CMC sections are consistently the most questioned part of a dossier because they directly demonstrate manufacturing control and product quality.
Specific issues that recur across submissions include:
- Insufficient analytical method validation: Methods are described but validation data does not cover all required parameters, or the validation was performed under conditions that do not reflect routine manufacturing.
- Incomplete stability data: Stability studies are ongoing at the time of submission, with insufficient real-time data to support the proposed shelf life, or stress testing has not been conducted according to ICH Q1A(R2).
- Poorly justified specifications: Acceptance criteria are set without linking them to clinical batches, safety thresholds, or manufacturing capability, leaving reviewers unable to assess whether limits are meaningful.
- Inadequate process description: Manufacturing process descriptions lack sufficient detail on critical process parameters and their acceptable ranges, making it impossible to evaluate process control.
- Impurity profiles not fully addressed: Degradation products or process-related impurities are identified but not qualified against ICH Q3A or Q3B thresholds.
What clinical and non-clinical data gaps cause submission delays?
Clinical and non-clinical data gaps that most commonly cause submission delays include missing dose justification, incomplete toxicology packages, and clinical study reports that do not align with the proposed indication or patient population. These gaps often require the applicant to conduct additional studies, which can add months or years to the development timeline.
On the non-clinical side, agencies frequently flag incomplete genotoxicity assessments, absent or inadequate reproductive and developmental toxicity data when the product targets a population where this is relevant, and safety pharmacology studies that were not conducted in line with ICH S7A or S7B. For clinical data, common problems include pivotal studies that were not designed as adequate and well-controlled trials, missing subgroup analyses for special populations, and risk management plans that do not adequately reflect the safety signals observed in trials.
A particularly frequent issue is the disconnect between the benefit-risk summary and the underlying data. When the clinical overview presents a more optimistic picture than the individual study reports support, reviewers identify this inconsistency quickly, and it raises broader questions about data integrity across the dossier.
How do formatting and administrative errors affect dossier quality?
Formatting and administrative errors reduce dossier quality by creating navigation barriers that slow the review process and signal a lack of attention to detail. While a formatting error alone rarely causes rejection, it creates a poor first impression and can obscure critical information that reviewers need to find quickly.
Common formatting and administrative issues in regulatory submissions include:
- Incorrect eCTD structure with broken hyperlinks or modules filed in the wrong location
- Inconsistent document versioning, where different sections reference different versions of the same study or document
- Missing or incomplete application forms, particularly for national procedures where country-specific annexes are required
- Translations that are absent or inaccurate for member states that require them
- Summaries in Module 2 that do not accurately reflect the content in Modules 3, 4, and 5
These issues are entirely preventable with a structured pre-submission quality check. Agencies are not obligated to look past administrative deficiencies, and in some procedures, a dossier can be declared invalid before scientific review even begins.
What gaps are specific to biologics and ATMPs?
Gaps specific to biologics and ATMPs in regulatory submissions typically relate to the complexity of characterizing living or biological systems, the traceability of starting materials, and the comparability of product manufactured at different scales or after process changes. These product types face a higher burden of characterization because their quality cannot be fully defined by the manufacturing process alone.
Biologics-specific gaps
For biologics, agencies frequently question the extent of structural and functional characterization, particularly for glycoproteins where glycan profiles significantly affect potency and immunogenicity. Reference standard qualification, cell bank characterization, and viral safety testing are also common areas where submissions fall short of expectations. Comparability exercises following manufacturing changes are often underpowered, relying on too few analytical methods or too small a dataset to demonstrate that the change has not adversely affected product quality.
ATMP-specific gaps
Advanced therapy medicinal products present additional challenges because the regulatory framework is still maturing and guidance documents are evolving. Common gaps include insufficient donor eligibility and traceability documentation for cell-based products, inadequate potency assay development that links the biological mechanism of action to a measurable release criterion, and risk-based justification for raw materials of biological origin. For gene therapy products, the manufacturing process description often lacks sufficient detail on vector production and purification, and long-term follow-up data commitments may not be adequately addressed in the risk management plan. Understanding the full scope of these expectations is easier when you learn more about the expertise behind the team supporting your submission.
How can companies avoid common dossier gaps before submission?
Companies can avoid common dossier gaps before submission by conducting structured gap analyses against current regulatory guidelines early in development, maintaining alignment between CMC, clinical, and regulatory teams throughout the program, and performing a formal pre-submission review before filing. Prevention is consistently more efficient than responding to agency questions after submission.
Practical steps that reduce the risk of gaps include:
- Map your dossier against the relevant guideline checklist for each module, identifying sections where data is missing, pending, or requires justification.
- Conduct a cross-module consistency check to confirm that the summaries in Module 2 accurately reflect the full study data in Modules 3, 4, and 5.
- Engage with the regulatory agency early through scientific advice or pre-submission meetings to validate your development strategy before committing to pivotal studies.
- Assign a single point of accountability for dossier quality who can identify gaps across functional areas and coordinate resolution before the filing deadline.
- Review recently published agency assessment reports for similar products to understand what questions reviewers are likely to raise.
Starting the gap analysis late, typically in the final weeks before submission, is one of the most common reasons avoidable issues make it into a filed dossier. Building gap analysis into each development milestone gives teams time to address deficiencies without compressing timelines.
How Starodub helps you close regulatory submission gaps
We work with biopharmaceutical and medical device companies at every stage of development to identify and resolve dossier gaps before they reach the agency. With over 400 completed projects and deep expertise across small molecules, biologics, vaccines, and ATMPs, our team knows exactly where reviewers look and what they expect to find.
Here is what we provide:
- Dossier gap analysis: A structured review of your submission package against current EMA, ICH, and national requirements, with a clear prioritized action list.
- CMC regulatory support: Expert guidance on specification justification, stability strategies, process validation documentation, and analytical method validation packages.
- Clinical and non-clinical dossier review: Assessment of your clinical overview, benefit-risk summary, and non-clinical package for consistency and completeness.
- ATMP and biologics expertise: Specialized support for complex product types where regulatory expectations are evolving and the margin for error is narrow.
- Pre-submission quality checks: A final review of eCTD structure, cross-references, and administrative completeness before you file.
If you want to file with confidence and reduce the risk of agency questions, contact Starodub today to discuss how we can support your next regulatory submission.
Related Articles
- What is the difference between PMDA and FDA approval processes?
- How do you manage regulatory compliance across multiple international markets?
- What are EMA requirements?
- What are the costs of medical device regulatory compliance?
- What are the benefits of ISO 13485 certification?
This content was generated with the help of AI and it may contain mistakes
